More articles from Idiopathic interstitial pneumonias

Autoantibody positivity (AAb+) in idiopathic pulmonary fibrosis (IPF): outcomes from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR)
Chad Newton, Tejaswini Kulkarni, Mary Beth Scholand, Kevin Flaherty, Zhongze Li, Sachin Gupta, Elana. J Bernstein

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2893; DOI: 10.1183/13993003.congress-2023.PA2893
Effects of nintedanib on circulating biomarkers in patients with progressive pulmonary fibrosis: subgroups by fibrotic pattern on HRCT
Toby M Maher, Francesco Bonella, Shervin Assassi, Imre Noth, Claudia Diefenbach, Carina Ittrich, Klaus B Rohr, Martin Kolb

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2879; DOI: 10.1183/13993003.congress-2023.PA2879
Real-World Safety and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Arata Azuma, Takashi Ogura, Yoshikazu Inoue, Yasuhiro Kondoh, Sakae Homma, Katsumi Tanaka, Kaori Ochiai, Kenya Muraishi, Yukihiko Sugiyama, Toshihiro Nukiwa

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2877; DOI: 10.1183/13993003.congress-2023.PA2877
Clinical and prognostic significance of p-ANCA antibodies positivity in Idiopathic Pulmonary Fibrosis
Giuseppe Muscato, Alessandro Libra, Giuseppe Ielo, Enrico Sciacca, Stefano Palmucci, Gianluca Sambataro, Carlo Vancheri

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2892; DOI: 10.1183/13993003.congress-2023.PA2892
Characteristics of patients with progressive fibrosing ILDs in the ILD-PRO Registry
Leonard Lobo, Yi Liu, Peide Li, Murali Ramaswamy, Aparna C Swaminathan, Srihari Veeraraghavan, Yanni Fan, Megan L Neely, Scott M Palmer, Amy L Olson

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2882; DOI: 10.1183/13993003.congress-2023.PA2882
Nocebo effect of nintedanib on gastrointestinal (GI) adverse events (AEs) in patients with interstitial lung diseases (ILDs)
Oliver Distler, Kristin B Highland, Arata Azuma, Tejaswini Kulkarni, Wim A Wuyts, Corinna Miede, Margarida Alves, Petros Sfikakis

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2878; DOI: 10.1183/13993003.congress-2023.PA2878
Impact of antifibrotic therapy on lung cancer incidence and mortality in patients with idiopathic pulmonary fibrosis
Yong Suk Jo, Kyung Joo Kim, Chin Kook Rhee, Yong Hyun Kim

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2880; DOI: 10.1183/13993003.congress-2023.PA2880
Five-year follow up analysis of Japanese ILD registry
Kazuya Tsubouchi, Naoki Hamada, Shoji Tokunaga, Toru Tsuda, Shohei Takata, Hiroshi Ishii, Yasuhiko Kitasato, Tomoaki Hoshino, Yosuke Sasahara, Kazuhiro Yatera, Masayuki Kawasaki, Masaki Fujita, Makoto Yoshida, Takashige Maeyama, Taishi Harada, Hiroshi Wataya, Chiharu Yoshii, Masashi Komori, Yuichi Mizuta, Kazunori Tobino, Eiji Harada, Yoichi Nakanishi, Isamu Okamoto

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2887; DOI: 10.1183/13993003.congress-2023.PA2887
Adverse Effects of Nintedanib – A Portent of Gender Inequality?
Dominic Sykes, Ellis Day, Kayinaat Ibrar, Amanda Bell, Mark Major, Alyn H Morice, Simon P Hart

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2876; DOI: 10.1183/13993003.congress-2023.PA2876
Continued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON
Wim A Wuyts, Francesco Bonella, Nazia Chaudhuri, Francesco Varone, Danielle Antin-Ozerkis, Jin Woo Song, Corinna Miede, Mihaela Dumistracel, Carl Coeck, Vincent Cottin

European Respiratory Journal Sep 2023, 62 (suppl 67) PA2874; DOI: 10.1183/13993003.congress-2023.PA2874

Main menu

User menu

Search

More articles from Idiopathic interstitial pneumonias

Pages

Contact us